Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials

References

• Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30(2):93–98.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Temin S, Giaccone G. 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage iv non-small-cell lung cancer. J Oncol Pract. 2012;8(1):63–66.
   PubMedGoogle Scholar
• Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98.
   PubMed Web of Science ®Google Scholar
• Han K, Jin J, Maia M, et al. Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. Aaps J. 2014;16(5):1056–1063.
   PubMed Web of Science ®Google Scholar
• Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107–2118.
   PubMed Web of Science ®Google Scholar
• Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–2926.
   PubMed Web of Science ®Google Scholar
• Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13(11):3264–3268.
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034–1041.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLOS One. 2012;7(5):e37563.
   PubMed Web of Science ®Google Scholar
• Xie HJ, Zhang X, Wei ZQ, et al. Effect of body mass index on survival of patients with stage I non-small cell lung cancer. Chin J Cancer. 2017;36(1):7.
   PubMedGoogle Scholar
• Dahlberg SE, Schiller JH, Bonomi PB, et al. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol.2013;8(9):1121–1127.
   PubMed Web of Science ®Google Scholar
• Duan P, Hu C, Quan C, et al. Body mass index and risk of lung cancer: Systematic review and dose-response meta-analysis. Sci Rep. 2015;5(1):16938.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1244–1259.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Harvie M, Cutress RI, et al. How to manage the obese patient with cancer. J Clin Oncol. 2016;34(35):4284–4294.
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Mangu PB, Anderson H, American Society of Clinical Oncology, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–1561.
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–e245.
   PubMed Web of Science ®Google Scholar
• Afshin A, Forouzanfar MH, Reitsma MB, GBD 2015 Obesity Collaborators, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
   PubMed Web of Science ®Google Scholar
• Del FC, Grant M, Koczywas M, et al. Management of Anorexia-Cachexia in Late Stage Lung Cancer Patients. J Hosp Palliat Nurs.2012;14
   Google Scholar
• Brunetti L, Na A, Chapy H, et al. The influence of body composition on intravenous immune globulin half-life in patients with primary immunodeficiency. Originally presented (by Luigi Brunetti) at the ACCP Annual Meeting. Pheonix, AZ, October 10, 2017.
   Google Scholar
• Steffens S, Grunwald V, Ringe KI, et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist. 2011;16(11):1565–1571.
   PubMed Web of Science ®Google Scholar
• Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer.2011;47(17):2560–2567
   PubMed Web of Science ®Google Scholar
• Renehan AG. Body fatness and bevacizumab-based therapy in metastatic colorectal cancer. Gut.2010;59(3):289–290.
   PubMed Web of Science ®Google Scholar
• Patel GS, Ullah S, Beeke C, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Med. 2015;4(10):1461–1471.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Bonnetain F, Gauthier M, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16(1):71–81.
   PubMed Web of Science ®Google Scholar
• Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut.2010;59(3):341–347.
   PubMed Web of Science ®Google Scholar
• Faruk Aykan N, Yildiz I, Sen F, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol. 2013;30(3):679.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Tsai CM, Tsao CJ, et al. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2013;82(2):276–281.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, BO17704 Study Group, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804–1809.
   PubMed Web of Science ®Google Scholar
• Mok T, Gorbunova V, Juhasz E, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol. 2014;9(6):848–855.
   PubMed Web of Science ®Google Scholar
• Besse B, Le Moulec S, Mazières J, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896–1903.
   PubMed Web of Science ®Google Scholar
• van der Meij BS, Schoonbeek CP, Smit EF, et al. Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks. Br J Nutr. 2013;109(12):2231–2239.
   PubMed Web of Science ®Google Scholar
• Shah S, Noone J, Blanchette CM, et al. Survival associated with cachexia among SEER-Medicare beneficiaries with lung cancer. J Clin Oncol. 2017;35(15_suppl):e18117–e18117.
   Web of Science ®Google Scholar
• Gaddam S, Brunetti L, Toscani M. Representation of adult obese subjects in pivotal clinical trials for products approved by the FDA. Presented at the 2017 Annual Drug Information Association Annual Meeting, June 18 2017.
   Google Scholar
• National Center for Health Statistics. Health, United States, 2016: with chartbook on long-term trends in health. Hyattsville, MD; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK453378/?report=printable
   Google Scholar
• von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):261–263.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.
   PubMed Web of Science ®Google Scholar
• Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247(4 Pt 2):F632–F636.
   PubMed Web of Science ®Google Scholar
• Hendrikx JJMA, Haanen JBAG, Voest EE, et al. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22(10):1212–1221.
   PubMed Web of Science ®Google Scholar
• Martins JP, Kennedy PJ, Santos HA, et al. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther. 2016;161:22–39.
   PubMed Web of Science ®Google Scholar
• Borvak J, Richardson J, Medesan C, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998;10(9):1289–1298.
   PubMed Web of Science ®Google Scholar
• Bastida C, Ruiz-Esquide V, Pascal M, et al. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. Br J Clin Pharmacol. 2018;84(4):716–725.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808.
   PubMed Web of Science ®Google Scholar
• Bai S, Jorga K, XinY, et al. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet. 2012;51:119–135.
   PubMed Web of Science ®Google Scholar
• HeinhuisKM, BeijnenJH, HendrikxJJMA. Follow up survey for implementation of fixed-dosing of monoclonal antibodies. Int J Clin Pharm. 2020;42(1):3–6.
   PubMed Web of Science ®Google Scholar
• Lennon H, Sperrin M, Badrick E, et al. The obesity paradox in cancer: a review. Curr Oncol Rep. 2016;18(9):56.
   PubMed Web of Science ®Google Scholar
• Morel H, Raynard B, d’Arlhac M, et al. Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer. Lung Cancer. 2018;126:55–63.
   PubMed Web of Science ®Google Scholar
• Hidayat K, Du X, Chen G, et al. Abdominal obesity and lung cancer risk: systematic review and meta-analysis of prospective studies. Nutrients. 2016;8(12):810.
   Web of Science ®Google Scholar
• Yang Y, Dong J, Sun K, et al. Obesity and incidence of lung cancer:a meta-analysis. Int J Cancer. 2013;132(5):1162–1169.
   PubMed Web of Science ®Google Scholar
• Gupta A, Majumder K, Arora N, et al. Premorbid body mass index and mortality in patients with lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;102:49–59.
   PubMed Web of Science ®Google Scholar
• Yap WK, Shih MC, Kuo C, et al. Development and validation of a nomogram for assessing survival in patients with metastatic lung cancer referred for radiotherapy for bone metastases. JAMA Netw Open. 2018;1(6):e183242.
   PubMed Web of Science ®Google Scholar
• Sepesi B, Gold KA, Correa AM, et al. The influence of body mass index on overall survival following surgical resection of non–small cell lung cancer. J Thorac Oncol. 2017;12(8):1280–1287.
   PubMed Web of Science ®Google Scholar
• Masel EK, Berghoff AS, Füreder LM, et al. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: a retrospective analysis of 624 patients. Eur J Cancer Care. 2017;26(6):e12707.
   Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635.
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE, Jänne PA, Wang X, et al. Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1448–1455.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 2017;18(9):1172–1181.
   PubMed Web of Science ®Google Scholar
• FriedmanHS, PradosMD, WenPY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar